| | | 甲醇日评20250711: 择机做多MTO利润 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 变化值 指标 | 单位 | 2025/7/10 | 2025/7/9 | | 变化值 | | | | | | | | (絶对值) | (相对值) | | | | MA01 | 元/吨 | 2434.00 | 2463.00 | -29.00 | -1.18% | | | 甲醇期货价格 | MA05 | 元/吨 | 2360.00 | 2380.00 | -20.00 | -0.84% | | | (收盘价) | MA09 | 元/吨 | 2372.00 | 2398.00 | -26.00 | -1.08% | | | | 太仓 | 元/吨 | 2390.00 | 2380.00 | 10.00 | 0.42% | | | | 山东 | 元/吨 | 2255.00 | 2275.00 | -20.00 | -0.88% | | 期现价格 | | 广东 | 元/吨 | 2412.50 | 2400.00 | 12.50 ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in animals Subcutaneous administration of TNX-801 yielded equivalent protection to the traditional percutaneous administration CHATHAM, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of develo ...

| | | 甲醇日评20250710: 择机做多MTO利润 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 变化值 指标 单位 2025/7/9 2025/7/8 | | | | | 变化值 | | | | | | | | (绝对值) | (相对值) | | | | MA01 | 元/吨 | 2434.00 | 2420.00 | 14.00 | 0.58% | | | 甲醇期货价格 | MA05 | 元/吨 | 2360.00 | 2347.00 | 13.00 | 0.55% | | | (收盘价) | MA09 | 元/吨 | 2372.00 | 2373.00 | -1.00 | -0.04% | | | | 太せ | 元/吨 | 2380.00 | 2405.00 | -25.00 | -1.04% | | | | 山东 | 元/吨 | 2275.00 | 2275.00 | 0.00 | 0.00% | | 期现价格 | | 广东 | 元/吨 | 2400.00 | 2415.00 | -15.00 | -0. ...

2025.07. 10 本文字数：2947，阅读时长大约5分钟 作者 | 第一财经 钱童心 16位"未来科学大奖"历年得主齐聚上海北外滩，共话推动人类未来发展的颠覆性科学技术。 7月8日，未来科学大奖十周年庆典在上海举行。未来科学大奖上海峰会联席主席、上海交通大学李 政道研究所副所长丁洪院士表示，希望激励更多年轻人投身科学前沿。 "未来科学大奖"被《自然》杂志称为"中国诺贝尔奖"，由民间公益组织颁发，设有生命科学奖、物质 科学奖、数学与计算机科学奖三大奖项，表彰在中国做出具有世界级影响力的科研成果，单项奖金高 达100万美元。 今年是未来科学大奖成立十周年。过去十年来，已有39位科学家获得未来科学大奖。真格基金创始 人徐小平表示："也许在100年后，比起诺贝尔奖，中国科学家更想获得未来科学大奖。" 寻找"不老药"和永久持续的能源 在生物医学领域，基础研究、应用研究和临床研究之间的鸿沟正在缩小，已进入相互融合、协同发展 的阶段。近年来，诞生了一批有望颠覆未来疾病治疗格局的具有潜力的疗法，包括一针预防心脏病或 治愈肿瘤的基因编辑疗法。 顶尖生物医学领域专家、香港中文大学校长卢煜明院士强调，如何在基础医学研究和临床 ...

Core Insights - The RESILIENT trial data demonstrates that TNX-102 SL significantly reduces fibromyalgia pain compared to placebo, confirming previous findings from the RELIEF trial [1][2] - If approved, TNX-102 SL will be the first new drug for fibromyalgia in over 15 years, with a PDUFA target date set for August 15, 2025 [1][2] Company Overview - Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for pain management and central nervous system disorders [8] - The company has submitted a New Drug Application (NDA) for TNX-102 SL based on two statistically significant Phase 3 studies [2][8] Study Details - The RESILIENT study was a randomized, double-blind, placebo-controlled trial involving 457 adults with fibromyalgia across 33 sites in the U.S. [2][7] - Participants received TNX-102 SL in two dosage phases: 2.8 mg for two weeks followed by 5.6 mg for twelve weeks, with a primary endpoint of pain reduction assessed over fourteen weeks [2][7] Efficacy Results - TNX-102 SL achieved a least-squares mean reduction of 1.8 points on the eleven-point daily pain numeric rating scale, compared to a 1.2-point reduction for placebo, indicating high statistical significance [2][7] - Statistically significant improvements were also noted across all six prespecified key secondary endpoints, including various patient-reported outcomes [2][3] Safety Profile - TNX-102 SL was generally well tolerated, with the most common adverse events being mild and transient, such as oral tingling/numbness and a bitter aftertaste [3] - No serious drug-related adverse events or deaths were reported, highlighting a favorable risk-benefit profile [3] Fibromyalgia Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain, fatigue, and sleep disturbances [4] - Current treatment options are often met with dissatisfaction from both physicians and patients, indicating a significant unmet need in the market [4] Product Information - TNX-102 SL is a patented sublingual formulation of cyclobenzaprine hydrochloride designed for rapid absorption and reduced side effects [5][6] - The drug is also being explored for other indications, including acute stress reaction, Long COVID, and alcohol use disorder [5][8]

| | | 甲醇日评20250709: 择机做多MTO利润 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 变化值 指标 单位 2025/7/8 2025/7/7 | | | | | 要你值 | | | | (绝对值) | | | | | (相对值) | | | | MA01 | 元/吨 | 2420.00 | 2435.00 | -15.00 | -0.62% | | | 甲醇期货价格 | MA05 | 元/吨 | 2347.00 | 2358.00 | -11.00 | -0.47% | | | (收盘价) | MA09 | 元/吨 | 2373.00 | 2392.00 | -19.00 | -0.79% | | | | 太仓 | 元/吨 | 2405.00 | 2422.50 | -17.50 | -0.72% | | | | 山东 | 元/吨 | 2275.00 | 2290.00 | -15.00 | -0.66% | | 期现价格 | | 广东 | 元/吨 | 2415.00 | 2432.50 | -17. ...

| | 里文大机/ | | --- | --- | | | 国内期价: 甲醇圭力MA2509弱势下跌, 开2390元/吨, 收2392元/吨, 跌23元/吨, 成交547156手, 持仓685709, 缩量 | | 资讯 | 减仓。交易日内合约均有成交; | | | 国外资讯: 今日远月到港的非伊甲醇船货参考商谈275-282美元/吨，缺乏主动固定价报盘听闻，远月到港的非伊船货参考 | | | 商谈在+1.6-2%; 中东其它区域方面, 远月到港的中东其它区域船货参考商谈在+1.1-2%, 关注近期部分工厂实际招标结 | | | 景。 | | | 【交易策略】 前一交易日, MA亮荡走低, 夜盘收于2386。我们认为甲醇短期或偏弱壳荡。从估值上看, 上游煤头利润仍然较高,而下游 | | | 综合利润相对较差，甲醇估值相对较贵; 从驱动上看, 目前甲醇供需驱动不强, 华东地区基差有收敛需求, 前期她缘冲突加 | | 小结 | 剧了港口流动货源紧张的局势，导致华东地区基差大幅度走高，目前地绿同抄缓和. 伊朗多数装置重启, 加上内地与南美货 | | | 源的补充，港口现货紧张局面得到缓解，基差或通过华东观货价格下跌 ...

Core Insights - Tonix Pharmaceuticals announced that its vaccine candidate TNX-801 provides durable protection against monkeypox after a single dose [1][3] - The vaccine is well tolerated in immunocompromised animals, showing no evidence of spreading to blood or tissues even at high doses [2][3] - TNX-801 is designed to generate both humoral and cellular immunity and serves as a platform for delivering multiple protective antigens against various viral pathogens [3][4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on developing therapies for pain management and vaccines for public health challenges [6] - The company has a diverse development portfolio, including TNX-102 SL for fibromyalgia, which has a PDUFA goal date of August 15, 2025 [6] - Tonix's infectious disease portfolio includes TNX-801 for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent with a contract worth up to $34 million with the U.S. Department of Defense [6]

| 甲醇日评20250707: 择机做多MTO利润 | | | | | | | --- | --- | --- | --- | --- | --- | | 2025/7/4 | | 变化值 指标 单位 2025/7/3 | | | 变化值 | | | | | | (绝对值) | (相对值) | | MA01 | | 元/吨 2437.00 | 2450.00 | -13.00 | -0.53% | | 元/吨 | 甲醇期货价格 | MA05 2356.00 | 2366.00 | -10.00 | -0.42% | | MA09 | (收盘价) | 元/吨 2399.00 | 2414.00 | -15.00 | -0.62% | | 太仓 | | 元/吨 2445.00 | 2455.00 | -10.00 | -0.41% | | 元/吨 | | 山东 2292.50 | 2295.00 | -2.50 | -0.11% | | 元/吨 | | 厂东 2455.00 | 2455.00 | 0.00 | 0.00% | | | 期现价格 甲醇观货价格 | | | | | | 2090.00 | 及基差 ( ...

近日，2025RoBoLeague中国机器人足球联赛（以下简称"机超"）在北京亦庄打响。 作为国内首个机器人足球3V3 AI赛，同时也是2025世界人形机器人运动会首场测试赛， 此次"机超"最大 的 亮点是参赛机 器人无需遥控器控制，完全依靠AI策略自主运行 。 人形机器人能够不依赖遥控器控制而自主运行，这离不开 视觉传感器 的辅助。 视觉传感器是人形机器人 进行环境感知、实现自主决策与交互 的关键技术之一。在视觉系统的帮助下，人形 机器人得以感知环境并进行建构、识别目标并进行追踪，进而与物体进行交互。 作为人形机器人的核心零部件之一，视觉传感器中的 3D视觉传感器 与人形机器人最为适配，是人形机器人主 流视觉解决方案。它主要包括 激光雷达、多目立体视觉、结构光和飞行时间法（ToF） 等技术路线。在这些 技术的融合与支持下，人形机器人仿佛拥有了"眼睛"。 本文盘点了部分涉及人形机器人视觉技术的企业。 ▍奥比中光 奥比中光成立于2013年，主营业务是3D视觉感知产品的设计、研发、生产和销售，主要产品包括3D视觉传感 器、消费级应用设备和工业级应用设备。 自成立以来，奥比中光凭借出色的产品研发能力、百万级的产品量 ...